Glucagon and GLP-1 receptor co-agonist
Survodutide injection
SURV_SC
Doses in this pooled treatment
- Survodutide 0.3 mg subcutaneous once weekly
- Survodutide 0.9 mg subcutaneous once weekly
- Survodutide 1.8 mg subcutaneous once weekly
- Survodutide 2.7 mg subcutaneous once weekly
- Survodutide 1.2 mg injection
- Survodutide 1.8 mg injection
- Survodutide 6.0 mg subcutaneous once weekly
- Survodutide 0.6 mg subcutaneous once weekly
- Survodutide 2.4 mg subcutaneous once weekly
- Survodutide 3.6 mg subcutaneous once weekly
- Survodutide 4.8 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -8.79 (-13.56 to -3.44) | 0.36 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.48 (1.82 to 32.34) | 0.76 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 10.28 (2.26 to 35.68) | 0.64 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 9.46 (2.05 to 40.89) | 0.60 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 0.87 (0.27 to 2.84) | 0.66 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.55 (0.85 to 7.72) | 0.30 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 5.32 (1.95 to 14.09) | 0.17 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 7.08 (1.70 to 26.09) | 0.34 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 3.37 (1.09 to 10.42) | 0.10 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 3.14 (0.91 to 11.14) | 0.25 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.84 (1.37 to 19.71) | 0.26 |
Trials
- NCT06309992Multicentre, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH)2024 · 218 randomized · 48 weeks
- NCT04667377A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight2021 · 387 randomized · 46 weeks